Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions.
Torres Robles J et al.
The Journal of Biological Chemistry, 2025
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Disruptor: Computational identification of oncogenic mutants disrupting protein-protein and protein-DNA interactions.
Kugler V et al.
Communications Biology, 2023
Mutation in the Common Docking Domain Affects MAP Kinase ERK2 Catalysis and Stability.
Novak L et al.
Cancers, 2023
ERK2 Mutations Affect Interactions, Localization, and Dimerization.
Taylor CA et al.
Biochemistry, 2023
Prognosis and Characterization of Microenvironment in Cervical Cancer Influenced by Fatty Acid Metabolism-Related Genes.
Zhou Y et al.
Journal of Oncology, 2023
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
Sumazin P et al.
Journal of Hepatology, 2022
Targeting lectin-like oxidized low-density lipoprotein receptor-1 triggers autophagic program in esophageal cancer.
Li C et al.
Cell Death and Differentiation, 2022
Precision drugging of the MAPK pathway in head and neck cancer.
Ngan HL et al.
Npj Genomic Medicine, 2022
Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.
Abdulla FR et al.
Jid Innovations : Skin Science From Molecules to Population Health, 2022
Protein dynamics analysis identifies candidate cancer driver genes and mutations in TCGA data.
Sayılgan JF et al.
Proteins, 2021
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age.
Chakraborty R et al.
Cold Spring Harbor Perspectives in Medicine, 2021
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
Ngan HL et al.
Life Science Alliance, 2020
Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects.
Tomasovic A et al.
Nature Communications, 2020
An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila.
Kushnir T et al.
Genetics, 2020
Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma.
Ngan HL et al.
Npj Genomic Medicine, 2020
Functional divergence caused by mutations in an energetic hotspot in ERK2.
Taylor CA et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance.
Li S et al.
Nature Communications, 2019
STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.
D'Amico S et al.
Genes & Development, 2018
APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW et al.
Nature Communications, 2017
Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.
Chakraborty R et al.
Oncotarget, 2017
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.
Brenan L et al.
Cell Reports, 2016
Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase.
Qi H et al.
The Journal of Biological Chemistry, 2016
A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.
Zou Y et al.
Oncology Reports, 2016
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Krauthammer M et al.
Nature Genetics, 2015
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Goetz EM et al.
Cancer Research, 2014
Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC et al.
Nature, 2014
ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila.
Mahalingam M et al.
Oncology Reports, 2008
A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.
Arvind R et al.
International Journal of Oncology, 2005